Keyword: Catalent

Catalent plans $200 million investment to expand its drug manufacturing and drug product fill/finish at two plants.

CDMO Catalent is adding packaging equipment to the biologics plant in Indiana it picked up last year in a $950 million deal.

Abzena will invest $20 million in a cell manufacturing facility, and Catalent is spending $2.5 million on a clinical supply facility in China.

Here is some news of note for the week.

Cook Pharmica, a biologics manufacturing company Catalent bought last year, was hit with a Form 483 by the FDA.

CDMO Catalent will pay about $133 million for Boston-based Juniper Pharmaceuticals.

Allergan, which is maneuvering through a host of financial challenges, has landed a new CFO who can help figure out how to pay for the fixes.